Mitkari Bhimashankar, Kerkelä Erja, Nystedt Johanna, Korhonen Matti, Jolkkonen Jukka
Institute of Clinical Medicine-Neurology, University of Eastern Finland, Kuopio, Finland.
Finnish Red Cross Blood Service, Research and Cell Therapy Services, Helsinki, Finland.
J Cereb Blood Flow Metab. 2015 Mar;35(3):363-6. doi: 10.1038/jcbfm.2014.235. Epub 2015 Jan 7.
This study examined whether human bone marrow mesenchymal stromal/stem cells (BMMSCs) could alleviate the secondary pathology in the thalamus after middle cerebral artery occlusion (MCAO) in rats. Atypical accumulation of both amyloid-β (Aβ) and calcium in the thalamus was significantly higher in rats receiving the BMMSCs infusion 48 hours after MCAO as compared with the vehicle MCAO group. The elevated Aβ/calcium accumulation correlated with the level of impaired sensorimotor function. Although secondary pathology in the thalamus seems to be rodent specific, it needs to be taken into account because it may impair long-term behavioral recovery and negate therapeutic treatment effects.
本研究检测了人骨髓间充质基质/干细胞(BMMSCs)能否减轻大鼠大脑中动脉闭塞(MCAO)后丘脑的继发性病理改变。与MCAO模型组相比,MCAO术后48小时接受BMMSCs输注的大鼠丘脑内淀粉样β蛋白(Aβ)和钙的异常蓄积显著更高。Aβ/钙蓄积的升高与感觉运动功能受损程度相关。尽管丘脑的继发性病理改变似乎具有啮齿类动物特异性,但仍需加以考虑,因为它可能会损害长期行为恢复并抵消治疗效果。